We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
Read MoreHide Full Article
Key Takeaways
OPRX posted 11% revenue growth and $1.5M adjusted EBITDA, its best Q1 showing to date.
80% of OPRX's FY25 revenue guidance is covered by contracts; subscription share exceeds 5%.
OPRX's Gross margin dipped to 60.9% as a lower-margin DTC mix weighed on profitability.
OptimizeRx (OPRX - Free Report) kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and turning in $1.5 million in adjusted EBITDA, its strongest first-quarter performance to date. The digital health company’s cost discipline and strategic client engagement efforts translated into a narrower net loss and stronger operating cash flow of $3.9 million, supporting a cash balance of $16.6 million.
The company raised full-year revenue guidance to $101-$106 million and expects adjusted EBITDA between $13-$15 million, citing a strong pipeline. The company’s existing contracts are likely to generate more than 80% of the revenue guidance. A notable strategic shift is the move toward a subscription-based revenue model, with early adoption already exceeding 5% of projected revenues. This shift, coupled with a broad and scalable tech platform, is designed to smooth revenue flows, enhance margins and deepen client stickiness.
However, gross margins came in slightly lower at 60.9% versus 62% last year, reflecting a higher mix of lower-margin DTC managed services. While management aims to lift margins over time, the current mix suggests some near-term pressure depending on solution uptake.
Critically, pharma clients are increasingly focused on efficiency and ROI in their marketing budgets amid regulatory shifts and evolving channel strategies. OptimizeRx’s omnichannel platform — leveraging point-of-care integration and real-world patient targeting — appears well aligned with these priorities. Early results show a script lift of 25% and a 10:1 ROI, reinforcing its value proposition.
OptimizeRx is navigating macro uncertainty with agility, benefiting from a growing base of committed revenues, cost efficiencies and a pivot to subscriptions. Continued execution in monetizing data and deepening customer relationships will be key to sustaining profit growth as pharma spending recalibrates in an increasingly digital landscape.
Peer Performance
Veeva Systems (VEEV - Free Report) reported strong first-quarter fiscal 2026 results with $759 million in revenues, up 16.7% year over year, driven by robust adoption of Vault CRM and Crossix. Management remains optimistic despite macro uncertainty, emphasizing resilient subscription revenues and a growing product pipeline. Crossix, which offers short-cycle ROI on pharma marketing, is seeing over 30% year-over-year growth and is viewed as relatively insulated from budget pressure. The company is also advancing Veeva AI to deepen customer value and aims to increase commercial productivity, positioning itself as a critical partner as pharma clients prioritize efficiency and measurable outcomes.
Health Catalyst (HCAT - Free Report) delivered $79.4 million in first-quarter of 2025 revenue, up 6.3% year-over-year, with its tech platform Ignite driving 10% growth. Amid shifting pharma and healthcare funding, HCAT’s modular, lower-cost Ignite platform enables faster ROI and shorter sales cycles, making it attractive in constrained budget environments. The company sees strong client uptake, particularly from existing app users, and expects 40 net new Ignite clients in 2025. While some booking delays occurred due to Medicaid and research funding uncertainty, HCAT believes the long-term value and pricing flexibility of Ignite will sustain growth. Full-year guidance was maintained, reflecting confidence in pipeline conversion.
OPRX’s Price Performance, Valuation and Estimates
Shares of OptimizeRx have surged 176.4% year to date compared with the industry’s growth of 15%.
Image Source: Zacks Investment Research
OPRX’s forward 12-month P/S of 2.25X is lower than the industry’s average of 8.67X, and also lower than its five-year median of 3.63X. However, it carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX’s 2025 earnings per share suggests a 63.6% improvement from 2024.
Image: Bigstock
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
Key Takeaways
OptimizeRx (OPRX - Free Report) kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and turning in $1.5 million in adjusted EBITDA, its strongest first-quarter performance to date. The digital health company’s cost discipline and strategic client engagement efforts translated into a narrower net loss and stronger operating cash flow of $3.9 million, supporting a cash balance of $16.6 million.
The company raised full-year revenue guidance to $101-$106 million and expects adjusted EBITDA between $13-$15 million, citing a strong pipeline. The company’s existing contracts are likely to generate more than 80% of the revenue guidance. A notable strategic shift is the move toward a subscription-based revenue model, with early adoption already exceeding 5% of projected revenues. This shift, coupled with a broad and scalable tech platform, is designed to smooth revenue flows, enhance margins and deepen client stickiness.
However, gross margins came in slightly lower at 60.9% versus 62% last year, reflecting a higher mix of lower-margin DTC managed services. While management aims to lift margins over time, the current mix suggests some near-term pressure depending on solution uptake.
Critically, pharma clients are increasingly focused on efficiency and ROI in their marketing budgets amid regulatory shifts and evolving channel strategies. OptimizeRx’s omnichannel platform — leveraging point-of-care integration and real-world patient targeting — appears well aligned with these priorities. Early results show a script lift of 25% and a 10:1 ROI, reinforcing its value proposition.
OptimizeRx is navigating macro uncertainty with agility, benefiting from a growing base of committed revenues, cost efficiencies and a pivot to subscriptions. Continued execution in monetizing data and deepening customer relationships will be key to sustaining profit growth as pharma spending recalibrates in an increasingly digital landscape.
Peer Performance
Veeva Systems (VEEV - Free Report) reported strong first-quarter fiscal 2026 results with $759 million in revenues, up 16.7% year over year, driven by robust adoption of Vault CRM and Crossix. Management remains optimistic despite macro uncertainty, emphasizing resilient subscription revenues and a growing product pipeline. Crossix, which offers short-cycle ROI on pharma marketing, is seeing over 30% year-over-year growth and is viewed as relatively insulated from budget pressure. The company is also advancing Veeva AI to deepen customer value and aims to increase commercial productivity, positioning itself as a critical partner as pharma clients prioritize efficiency and measurable outcomes.
Health Catalyst (HCAT - Free Report) delivered $79.4 million in first-quarter of 2025 revenue, up 6.3% year-over-year, with its tech platform Ignite driving 10% growth. Amid shifting pharma and healthcare funding, HCAT’s modular, lower-cost Ignite platform enables faster ROI and shorter sales cycles, making it attractive in constrained budget environments. The company sees strong client uptake, particularly from existing app users, and expects 40 net new Ignite clients in 2025. While some booking delays occurred due to Medicaid and research funding uncertainty, HCAT believes the long-term value and pricing flexibility of Ignite will sustain growth. Full-year guidance was maintained, reflecting confidence in pipeline conversion.
OPRX’s Price Performance, Valuation and Estimates
Shares of OptimizeRx have surged 176.4% year to date compared with the industry’s growth of 15%.
Image Source: Zacks Investment Research
OPRX’s forward 12-month P/S of 2.25X is lower than the industry’s average of 8.67X, and also lower than its five-year median of 3.63X. However, it carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX’s 2025 earnings per share suggests a 63.6% improvement from 2024.
Image Source: Zacks Investment Research
OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.